Venus Remedies gets UK approval for chemotherapy drugs

The product will be sold by its German subsidiary, Venus Pharma GmbH

Chandigarh-based Venus Remedies has received market authorisation in the United Kingdom for Bleomycin 15,000 IU powder for solution for injection/infusion. The product will be distributed through its German subsidiary, Venus Pharma GmbH, the company informed exchanges on October 26.

Bleomycin 15,000 IU is a potent medication containing the active component bleomycin sulfate. It falls within the category of cytostatic drugs, a specialised class of medicines designed to combat cancer. These drugs, commonly referred to as chemotherapy, are well-regarded for their ability to target cancer cells and inhibit their uncontrolled proliferation.

Bleomycin can be administered as a standalone treatment or in combination with other cancer medications and radiotherapy. Its proven effectiveness and versatility in cancer therapy have led to its market authorisations in multiple countries across the globe.

Ashutosh Jain, CEO, Venus Pharma GmbH, expressed that obtaining market authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) is a momentous accomplishment for Venus Pharma GmbH. It enables the company to play a pivotal role in advancing cancer care and improving the quality of life for patients facing this challenging disease.

Venus Remedies is proud to hold a total of 15 market authorisations (MA) for Bleomycin products across the globe. As part of its efforts to make Bleomycin more accessible, the company has submitted sixteen additional applications to Ministries of Health (MOHS) around the world. Venus has secured 15 registrations for this drug across various regions, including Africa, Asia, the Middle East, the Commonwealth of Independent States (CIS), North America, and South America.

"We remain dedicated to enhancing healthcare solutions and are committed to pursuing additional authorizations to reach even more patients in need," said Saransh Chaudhary, CEO, Venus Medicines Research Center.